Online exercise program to improve quality of life for men with prostate cancer
An Individualised 8-week Remote Exercise Intervention to Improve QoL, Cardiometabolic Risk and Physical Activity Level in Men With Prostate Cancer Undergoing ADT Treatment.
This study tests whether an 8-week online exercise program can help improve the quality of life for men with prostate cancer who are on long-term hormone therapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | Male |
| Sponsor | University of Surrey Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Guildford, Surrey) |
| Trial ID | NCT05989854 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of an 8-week remote exercise and behavioral support program on the quality of life of men with prostate cancer. Participants will receive one remote supervised exercise session per week, focusing on those undergoing long-term hormone therapy. The aim is to determine if this online approach can effectively support prostate cancer patients and potentially be expanded to a larger population in the future.
Who should consider this trial
Good fit: Ideal candidates are men with prostate cancer who are on long-term hormone therapy.
Not a fit: Patients currently undergoing chemotherapy or radiation therapy, or those with high cardiovascular risk, may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could enhance the quality of life for men with prostate cancer by providing accessible exercise support.
How similar studies have performed: Other studies have shown promise in using remote exercise interventions for cancer patients, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Have had an orchiectomy OR; * Are receiving a GnRH agonist/antagonist OR; * Are currently receiving Abiraterone, Enzalutamide, Apalutamide or Darolutamide * Long-term retention is planned (intending to remain on the above stated treatments for at least the next 6 months). Exclusion Criteria: * Patients who are currently classed as in active treatment i.e. are currently receiving chemotherapy/radiation therapy (Note: Patients that are included in the study but after inclusion are moved onto chemo/radiation therapy, will still be able to participate in the project). * Patients who are stratified as high risk for having a cardiovascular event. * Acute illness; or any musculoskeletal, cardiovascular or neurological disorder that could inhibit or put them at risk from exercising, as determined by screening and their clinician. * Men with painful or unstable bony metastases.
Where this trial is running
Guildford, Surrey
- University of Surrey — Guildford, Surrey, United Kingdom (Recruiting)
Study contacts
- Study coordinator: Ralph Manders, PhD
- Email: r.manders@surrey.ac.uk
- Phone: +44(0)1483688668
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.